PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsAnlotinib
Catequentinib
Catequentinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Searched
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
428 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD00228952081333
Thyroid neoplasmsD013964EFO_000384132115
Thyroid diseasesD013959E00-E0722114
Papillary thyroid cancerD0000772731112
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung neoplasmsD008175C34.9072710138
CarcinomaD002277C80.0212416
Hepatocellular carcinomaD006528C22.02528
Small cell lung carcinomaD055752437
Liver neoplasmsD008113EFO_1001513C22.01416
Colorectal neoplasmsD0151791325
AdenocarcinomaD0002301314
Endometrial neoplasmsD016889EFO_0004230314
Stomach neoplasmsD013274EFO_0003897C16414
SarcomaD012509324
Show 13 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C806813
RecurrenceD012008166
Gastrointestinal neoplasmsD005770C26.955
Digestive system neoplasmsD00406755
Pancreatic neoplasmsD010190EFO_0003860C2533
Squamous cell carcinomaD00229433
Esophageal squamous cell carcinomaD00007727733
Esophageal neoplasmsD004938C1533
Gastrointestinal diseasesD00576733
Digestive system diseasesD004066EFO_0000405K92.933
Show 23 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver diseasesD008107EFO_0001421K70-K7711
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCatequentinib
INNcatequentinib
Description
Anlotinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 3, fibroblast growth factor receptor 1, and vascular endothelial growth factor receptor 1.
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Identifiers
PDB
CAS-ID1058156-90-3
RxCUI
ChEMBL IDCHEMBL4303201
ChEBI ID
PubChem CID25017411
DrugBankDB11885
UNII IDGKF8S4C432 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,582 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
241 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use